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Abstract
There is considerable variability in the susceptibility of smokers to develop chronic obstructive pulmonary disease (COPD).
The only known genetic risk factor is severe deficiency of a1-antitrypsin, which is present in 1–2% of individuals with COPD.
We conducted a genome-wide association study (GWAS) in a homogenous case-control cohort from Bergen, Norway (823
COPD cases and 810 smoking controls) and evaluated the top 100 single nucleotide polymorphisms (SNPs) in the family-
based International COPD Genetics Network (ICGN; 1891 Caucasian individuals from 606 pedigrees) study. The
polymorphisms that showed replication were further evaluated in 389 subjects from the US National Emphysema
Treatment Trial (NETT) and 472 controls from the Normative Aging Study (NAS) and then in a fourth cohort of 949
individuals from 127 extended pedigrees from the Boston Early-Onset COPD population. Logistic regression models with
adjustments of covariates were used to analyze the case-control populations. Family-based association analyses were
conducted for a diagnosis of COPD and lung function in the family populations. Two SNPs at the a-nicotinic acetylcholine
receptor (CHRNA 3/5) locus were identified in the genome-wide association study. They showed unambiguous replication in
the ICGN family-based analysis and in the NETT case-control analysis with combined p-values of 1.48610210, (rs8034191)
and 5.74610210 (rs1051730). Furthermore, these SNPs were significantly associated with lung function in both the ICGN and
Boston Early-Onset COPD populations. The C allele of the rs8034191 SNP was estimated to have a population attributable
risk for COPD of 12.2%. The association of hedgehog interacting protein (HHIP) locus on chromosome 4 was also
consistently replicated, but did not reach genome-wide significance levels. Genome-wide significant association of the HHIP
locus with lung function was identified in the Framingham Heart study (Wilk et al., companion article in this issue of PLoS
Genetics; doi:10.1371/journal.pgen.1000429). The CHRNA 3/5 and the HHIP loci make a significant contribution to the risk of
COPD. CHRNA3/5 is the same locus that has been implicated in the risk of lung cancer.
Citation: Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, et al. (2009) A Genome-Wide Association Study in Chronic Obstructive Pulmonary Disease (COPD):
Identification of Two Major Susceptibility Loci. PLoS Genet 5(3): e1000421. doi:10.1371/journal.pgen.1000421
Editor: Mark I. McCarthy, University of Oxford, United Kingdom
Received October 22, 2008; Accepted February 12, 2009; Published March 20, 2009
Copyright:  2009 Pillai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The Bergen and ICGN populations were funded by GlaxoSmithKline. SGP, GZ, XK, AR and WA are employees of GlaxoSmithKline. The NETT/NAS and
Boston Early-Onset COPD replication studies were supported by U.S. National Institutes of Health grants R01HL075478, U01HL089856, P01HL083069,
R01HL084323, and K08HL080242. The National Emphysema Treatment Trial was supported by the National Heart, Lung, and Blood Institute (N01HR76101,
N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112,
N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, N01HR76119), Centers for Medicare and Medicaid Services, and the Agency for Healthcare
Research and Quality. The Normative Aging Study is supported by the Cooperative Studies Program/Epidemiology Research and Information Center of the US
Department of Veterans Affairs and is a component of the Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), Boston, MA. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sreekumar.g.pillai@gsk.com (SGP); d.goldstein@duke.edu (DBG)
. These authors contributed equally to this work.
Introduction
COPD is expected to be the third leading cause of worldwide
mortality and the fifth leading cause of morbidity by the year 2020
[1]. Cigarette smoking is the major risk factor for COPD but
smokers show considerable variation in their risk of developing
airflow obstruction. Familial aggregation studies suggest a strong
genetic component to this risk [2–8]. However the only proven
genetic risk factor for COPD is severe deficiency of a1-antitrypsin
[9], which is present in only 1–2% of individuals with COPD. This
suggests that other genes have yet to be identified that predispose
smokers to airflow obstruction. We report the first genome wide
association study (GWAS) for COPD. Our primary discovery
sample was a case-control population collected from Bergen,
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Norway, and we used three independent study cohorts to further
evaluate the top associations emerging from the GWAS analysis.
Results
Baseline characteristics of the subjects used in the GWAS and
subsequent replication studies are presented in Table 1.
Genome-Wide Association Results
We used a multi-stage replication design (Figure 1) for this
study. The genome-wide association analyses of the COPD case-
control status in the Bergen cohort identified several significant
associations, including three SNPs on chromosome 5 that reached
the level of genome-wide significance (Table S1). The Q-Q plot
showing the distribution of observed P values from the discovery
cohort is shown in online Figure S1. The top 100 SNPs were then
evaluated in the ICGN population and 8 were replicated at a
nominal p value of 0.05 (SNP rs11219732 showed inconsistent risk
alleles in the Bergen and ICGN population and hence was not
considered further, Table 2). Two of the three SNPs (rs7727670
and rs7341022 on chromosome 5) that showed genome-wide
significance in the Bergen cohort did not replicate in the ICGN
population. The SNPs showing the most definitive evidence for
replication were rs8034191 and rs1051730 in the CHRNA3/5
locus.
Several additional SNPs were later analyzed in the CHRNA3/5
region in the Bergen and ICGN populations (Table S2). One non-
synonymous polymorphism in CHRNA5 (rs16969968) which coded
for the substitution of an asparagine for an aspartic acid at amino
acid 398) was associated with COPD in the Bergen (p= 8.861024)
and ICGN (p= 2.7861026) cohorts (combined p value
5.0861028). Since this SNP showed a weaker association than
both rs8034191 and rs1051730 it was not considered as a causal
variant.
We then tested the 7 SNPs that showed definite or nominal
significance in the NETT-NAS case-control population, and the
results are provided in Table 2. These results further confirmed
the association of two SNPs at the CHRNA3/5 locus with COPD
(p= 2.561023, OR=1.43, combined p value: 1.48610210 for
rs8034191 and p= 0.017, OR=1.32, combined p value
5.74610210 for rs1051730). Two SNPs (rs1828591 and
rs13118928) at the HHIP locus on chromosome 4 also showed
consistent replication across the three cohorts, but the combined p
values did not reach genome-wide significance (1.4761027 and
1.6761027 respectively).
The only significant associations in the Boston Early-Onset
COPD families were with the rs8034191 and rs1051730 SNPs at
the CHRNA 3/5 locus (p = 0.03 and 0.03 respectively) and the
rs1828591 and rs13118928 SNPs at the HHIP locus (p = 0.0025
and 0.0014 respectively) with post bronchodilator FEV1. None of
the SNPs was significantly associated with a diagnosis of COPD.
Since the ICGN cohort had recruited subjects with a wide range of
lung function, we also analyzed the association of the CHRNA 3/
5 markers with post bronchodilator FEV1 after adjusting for age,
height, gender, pack years and smoking status. The results show
that CHRNA 3/5 SNPs were associated with FEV1 in the ICGN
population (p values 1.0461024 and 1.7561025 for rs8034191
and rs1051730 respectively).
The COPD associated region on chromosome 15 spans seven
genes (Figure 2). Cholinergic nicotinic receptor subtypes a3, a5
Table 1. Characteristics of the primary screening and replication populations.
COPD Case-Control Data ICGN Family Data NETT/NAS Boston Early Onset COPD
Cases Controls Probands Siblings NETT Cases NAS Controls Probands Relatives
Subjects 823 810 606 1285 389 472 127 822
Age (6SD) 65.41 (610.15) 55.45 (69.58) 58.43 (65.40) 58.02 (69.78) 67.44 (65.82) 69.79 (67.53) 48.09 (64.70) 46.25 (618.75)
Female (%) 330 (40.10%) 402 (49.63%) 244 (40.26%) 640 (49.80%) 139 (35.73%) 0 95 (74.80%) 458 (55.72%)
Post-FEV1 in liters (6SD) 1.59 (60.71) 3.25 (60.74) 1.11 (60.44) 2.36 (60.98) 0.81 (60.26) 3.03 (60.50)
b 0.65 (60.28) c 2.84 (61.03) c
Post-FEV1, % pred (6SD) 50.26 (617.33) 93.91 (69.22) 36.19 (612.94) 77.46 (625.92) 28.00 (67.36) 99.96(613.12)
b 21.86 (68.44) c 87.22 (620.27) c
Post-FEV1/FVC ratio (6SD)
a 0.52 (60.13) 0.79 (60.04) 0.37 (60.12) 0.61 (60.15) 0.32 (60.06) 0.79 (60.05) b 30.88(610.09) c 73.44 (612.85) c
Pack-years of smoking (6SD) 31.83 (618.86) 19.40(613.43) 51.59 (626.71) 40.49 (624.62) 66.36(630.37) 40.30 (627.56) 38.86 (621.87) 18..96 (625.04)
Current smoking status (%) 383 (46.54%) 342 (42.22%) 205 (33.83%) 653 (50.82%) 0 31 (6.57%) 16 (12.60%) 248 (30.17%)
aNote: FEV1/VC was used for the ICGN Family Data, with VC determined by the higher of FVC and SVC.
bPre-bronchodilator spirometry measurements were used in the NAS.
cPost-bronchodilator spirometry measurements available in 118 probands and 789 relatives.
doi:10.1371/journal.pgen.1000421.t001
Author Summary
There is considerable variability in the susceptibility of
smokers to develop chronic obstructive pulmonary disease
(COPD), which is a heritable multi-factorial trait. Identifying
the genetic determinants of COPD risk will have tremen-
dous public health importance. This study describes the
first genome-wide association study (GWAS) in COPD. We
conducted a GWAS in a homogenous case-control cohort
from Norway and evaluated the top 100 single nucleotide
polymorphisms in the family-based International COPD
Genetics Network. The polymorphisms that showed
replication were further evaluated in subjects from the
US National Emphysema Treatment Trial and controls from
the Normative Aging Study and then in a fourth cohort of
extended pedigrees from the Boston Early-Onset COPD
population. Two polymorphisms in the a-nicotinic acetyl-
choline receptor 3/5 locus on chromosome 15 showed
unambiguous evidence of association with COPD. This
locus has previously been implicated in both smoking
behavior and risk of lung cancer, suggesting the possibility
of multiple functional polymorphisms in the region or a
single polymorphism with wide phenotypic consequences.
The hedgehog interacting protein (HHIP) locus on
chromosome 4, which is associated with COPD, is also a
significant risk locus for COPD.
COPD GWAS: Identification of Two Major Loci
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and b4; IREB2, PSMA4, NP_001013641.2 (a gene with unknown
function) and Q9UD29 (Surfactant protein B (SP-B)-binding
protein). A partial map of the region is shown in online Figure
S2. SP-B binding protein is a DNA binding protein which binds to
the promoter of SP-B and affects its expression [10]. Since SP-B is
a critical surfactant in the lungs [11], we sequenced the SP-B
binding protein in 30 COPD subjects who are homozygous for the
risk allele of rs8034191 but did not identify any polymorphisms in
this gene.
Interaction with Smoking
The p values reported above were based on the adjusted
analyses correcting for smoking exposure. The results from the
unadjusted association analyses for COPD status were highly
significant (Bergen 261024 and 461024; ICGN 7.4661027 and
1.4061026; NETT/NAS, 2.061025 and 2.561024 and com-
bined p values of 1.86610212 and 6.6610211 for rs8034191 and
rs1051730 respectively; Table S3). Although the adjustments for
smoking exposure attenuated the p values, they still remained
highly significant (Table 2). In the Norwegian discovery cohort, a
significant genotype-by-environment interaction (P = 0.002,
Table 3) was observed with a substantially higher risk of COPD
in current smokers carrying the rs8034191 C allele (OR=2.00)
than in former smokers (OR=1.10). In the overall population, the
C allele of rs8034191 was estimated to have a population
attributable risk of 12.2% for COPD. This risk was 14.3% in
current smokers and 3.1% in former smokers. The p values were
attenuated in the ICGN family-based population following
adjustment for age, sex, pack-years of smoking and center but
remained highly significant (Table 2). We identified a SNP by
pack-years interaction (p= 0.0037 for rs8034191), however no
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Figure 1. Study design. SNP: Single Nucleotide Polymorphism.
aICGN: International COPD Genetics Network families. bNETT: National
Emphysema Treatment Trial. cNAS: Normative aging study. d One of the
SNPs genotyped in NETT/NAS population (rs735243) was not success-
fully genotyped in the BEOCOPD population.
doi:10.1371/journal.pgen.1000421.g001
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Figure 2. Region of Association around CHRNA3/CHRNA5. Annotated sections: Top: Linkage disequilibrium (r2) for all HapMap SNPs with
rs8034191, showing an LD extension covering CHRNA3/CHRNA5. [red] r2$0.8, [yellow] 0.5#r2,0.8, [gray] 0.3#r2,0.5, [blue] 0.2#r2,0.3. Middle:
Recent selection score. Bottom: genic context. Exons are depicted as blue vertical lines/rectangles, while introns are depicted as blue horizontal lines.
Annotations were done using the WGAViewer software [31].
doi:10.1371/journal.pgen.1000421.g002
Table 3. Genotype counts and allele frequencies for rs8034191 by case-control status and smoking status in the Bergen discovery
cohort.
Population Smoking Status/Amount Genotype MAF (C)
TT CT CC
case All 326 375 122 0.376
ctrl All 391 328 91 0.315
case Current Smoker 139 186 58 0.394
case Current Non-smoker 186 188 64 0.361
ctrl Current Smoker 177 135 30 0.285
ctrl Current Non-smoker 213 193 61 0.337
case Heavy Smoker Note 1 221 251 85 0.378
case Light Smoker 105 124 37 0.372
ctrl Heavy Smoker 128 115 34 0.330
ctrl Light Smoker 263 213 57 0.307
case Heavy Smoker Note 2 233 247 79 0.362
case Light Smoker 92 127 43 0.406
ctrl Heavy Smoker 122 105 28 0.316
ctrl Light Smoker 268 223 63 0.315
Norwegian population controls Population sample 246 251 54 0.326
Note 1: Heavy smoker defined by pack-years of smoking (grouped by log transformed median = 3.11).
Note 2: Heavy smoker defined by length of smoking history (grouped by median = 41.5 yr).
doi:10.1371/journal.pgen.1000421.t003
COPD GWAS: Identification of Two Major Loci
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significant SNP by current smoking status interaction (p= 0.85)
was detected in the ICGN population.
Testing directly for an association between the amount of
smoking, measured as pack-years, within cases and controls
respectively, with the SNP rs8034191, demonstrated no such
association in the Norway discovery cohort (P = 0.63 and 0.47,
respectively). We also carried out tests comparing allele frequen-
cies for current and former smokers and heavy and light smokers,
(two different definitions, using pack years of smoking and length
of smoking history) within cases and controls separately (Table 3).
The only significant association observed was in comparing
current and former smokers among the controls (p = 0.028).
Similarly, the rs8034191 SNP was not associated with pack-years
smoked in the NETT cases or in the NAS controls.
Discussion
We have demonstrated and replicated genetic associations
between SNPs at the CHRNA3/5 locus and COPD in four study
populations. The estimated population attributable risk from this
locus was 12.2% and represents the discovery of a common major
locus contributing to COPD in the general population. However, a
potential complication with the interpretation of these findings is the
possibility that differences in smoking behavior, likely related to
nicotine addiction, between COPD cases and controls may drive
the observed association. This is similar to the recently reported
association of CHRNA3/5 SNPs with lung cancer [12–14].
In the current study populations, only limited assessment of
nicotine addiction is available: (i) whether subjects were still
smoking at the time of study participation, and (ii) their lifetime
smoking intensity. Thus, we have limited ability to disentangle a
genetic determinant of smoking behavior from a genetic
determinant of COPD through an alternative pathway. There
are several pieces of evidences to suggest that there could be a
direct effect of CHRNA3/5 locus on COPD, independent of
smoking behavior. First, to the extent that smoking behavior is
captured in pack-years, this effect should be factored out by the
statistical design in which the discovery analyses used a logistic
regression model incorporating pack-years, age and gender as
covariates. The adjustments for pack-years smoked, age and
gender were also performed in all the replication analyses.
However, pack-years smoked only partially capture smoking
behavior. Many other factors, such as depth of inhalation, number
of puffs per cigarette, and age of starting smoking are also likely to
affect the toxicant exposure and effect. Second, we also tested
directly for an association between the amount of smoking,
measured as pack-years, within cases and controls with the SNP
rs8034191. There was no significant association between the SNPs
and pack-years of smoking in the Bergen and NETT/NAS
populations. This is consistent with the observed allele frequency
among the Norwegian pediatric general population sample (minor
allele frequency = 0.326, n= 551) which is between that observed
for cases and controls and not significantly different from either.
We observed a genotype-by-environment interaction between
the risk of the rs8034191 genotype and current smoking status on
COPD in the Norwegian sample (P= 0.002, Table 3), showing a
substantially higher risk of COPD in current smokers carrying the
rs8034191 C allele (OR=2.0) than in former smokers (OR=1.1).
There are several possible explanations for this gene-by-environ-
ment interaction. First, it could relate to nicotine addiction;
smokers that have greater difficulty quitting smoking may be more
likely to develop COPD. Alternatively, it could indicate that a
subset of individuals is at greater risk for developing COPD if they
continue to smoke. A similar interaction with current smoking was
not identified in the ICGN families. Since all the COPD patients
in the NETT population were former smokers, we could not
address this question in the NETT/NAS study.
The association of smoking dependence was explored in the lung
cancer report by Hung and colleagues [13] who did not detect any
association with individual Fagerstrom indices of nicotine addiction
or when comparing controls with a heaviness of smoking index
(HSI). Another lung cancer report by Amos and colleagues [12] did
show weak evidence for association with smoking behavior, while a
further report by Thorgeirsson and colleagues[14] showed very
strong association with smoking behavior. Association of this locus
with nicotine dependence has been reported in two other studies
[15,16]. Thus, it is reasonable to conclude that the variants may
affect smoking behavior, at the same time as having a significant
effect on COPD and other smoking related diseases such as lung
cancer and peripheral arterial disease [12–14].
The CHRNA3/5 SNPs were also associated with lung function
(FEV1) in the ICGN and BEOCOPD populations. These SNPs
were shown to be associated with FEV1 in the British Birth Cohort
(rs8034191 and rs1051730, p= 0.029 and 0.023, respectively
(http://www.b58cgene.sgul.ac.uk/, accessed [3/7/2008]). Histori-
cally, nicotinic receptors are classified as neuronal or muscle-type,
based on their initial site of identification and composite subunits
[17]. Cholinergic activity in the airways primarily induces tracheo-
bronchial smooth muscle contraction and mucous secretion.
However, there is an increasing body of literature showing the
importance of extra-neuronal cholinergic signaling [18] in the lung.
The association of the SNPs at the chromosome 4 HHIP
(Hedgehog-Interacting Protein) locus is also interesting, though it
did not reach the stringent genome-wide significance levels in the
populations studied in this manuscript. These SNPs were also
associated with FEV1 in the BEOCOPD study (rs1828591 and
rs13118928, p = 0.0025 and 0.0014). The same SNPs are also
associated with FEV1 in the British Birth Cohort (rs1828591 and
rs13118928, p = 0.039 and 0.038, respectively) but were not
associated with FEV1 in the ICGN population.
In another manuscript in this issue of the journal, genome-wide
association analysis results for FEV1/FVC in the Framingham Heart
Study (FHS) are reported (Wilk et al). Due to differences in
genotyping platforms, the most significantly associated SNPs on
chromosome 15 in our study were not genotyped in FHS. Analysis of
the genotyped SNPs in the chromosome 15 region in the FHS
indicated no significant association with COPD, but association with
FEV1 percent predicted was observed with one SNP in LD with
rs8034191 (rs11636431 p value 0.007). Evaluation of the imputed
data for the most significantly associated SNPs in our populations did
not show association with COPD in FHS. Several factors could
contribute to the absence of association to the COPD phenotype in
FHS: (1) The FHS cohort is a population-based collection, while our
studies evaluated populations ascertained specifically for COPD; (2)
The FHS cohort was recruited over three decades, while our cohorts
represent more recent recruitments (in the last 5–10 years)-smoking
habits have changed over time, and it is also possible that COPD
clinical characteristics have changed over this period; (3) Our cohorts
include a greater proportion of severe COPD subjects than in FHS;
and (4) There could be differences in linkage disequilibrium patterns
between study populations. Further studies will be required to define
the specific genetic determinants influencing COPD on chromosome
15, the relationship of these genetic factors to smoking behavior, and
the characteristics of COPD subjects influenced by these genetic
determinants.
The association of the Chromosome 4 region in the FHS cohort
was genome-wide significant for the FEV1/FVC ratio and was also
associated with COPD. This association was subsequently replicated
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in the Family Heart Study population. Though the HHIP locus
association in our study did not reach genome-wide significance, the
additional evidence from the FHS and Family Heart Study
underscore the importance of this locus on COPD susceptibility.
We used independent populations with varying COPD severity,
independent genotyping platforms and stringent statistical signifi-
cance criteria to define genome-wide significant associations.We used
consensus criteria for replication using a multi-stage replication
design with similar phenotypes, the same genetic model and direction
of association [19]. The levels of statistical significance of the
association for our most significant results in the CHRNA3/5 region
were consistent in all of the populations studied and are unlikely to be
false positive results. The p values after adjusting for multiple testing
using the most conservative Bonferroni correction were 7.361025
and 2.8361024 for the SNPs rs8034191 and rs1051730 respectively.
Though this can be considered as strength, the conservative approach
for SNP confirmation that we have used may lead to larger false
negative rates. However, with the inconsistent results of previous
complex disease genetic association studies, we contend that a
conservative approach is appropriate. We selected only the top 100
SNPs from the GWAS for subsequent replication study and a larger
number of significant associations may have been uncovered if more
of the most promising SNPs had been followed up. A negative
association in the replication studies may not rule out a true
association, since the power to detect association in the replication
populations may be limited. The primary replication cohort (ICGN)
is moderately powered to detect the replicated associations. Though
the sample sizes of the NETT/NAS and BEOCOPD studies are
relatively low, these studies include a large percentage of severely
affected individuals, who may be enriched for COPD susceptibility
genes. This likely account for the high rate of replication in these
populations. COPD is a heterogeneous disease and we used a
spirometry-based definition for COPD in all of the populations.
Differences in smoking exposure, current smoking status, entry
criteria and geographic origin of the cohorts might contribute to
phenotypic heterogeneity and may lead to lack of replication. The
fact that the replicated associations holds-up strongly and consistently
in all the populations shows that phenotypic heterogeneity likely has
little effect on the most significant results.
In summary, we have identified robust evidence of association
of COPD with the a-nicotinic receptor (CHRNA 3/5) and HHIP
loci. The hedgehog (Hh) gene family encodes signaling molecules
that play an important role in regulating morphogenesis and the
HHIP locus may play a role lung development. Although there is
evidence of association of CHRNA 3/5 locus with nicotine
addiction, both this study and recent reports of a lung cancer
association [12–14] with the same alleles suggest that this region
may be involved in more than nicotine addiction, and may
potentially have direct functional relevance in the development of
COPD, lung cancer, peripheral arterial disease, and other
smoking related conditions. The first-degree relatives of both
lung-cancer patients and COPD patients have higher rates of
impaired forced expiratory flow rates than relatives of patients
with non-pulmonary disease [20], suggesting that susceptibility to
lung cancer and COPD share common familial components. The
association of CHRNA 3/5 locus with COPD, lung cancer, and
peripheral arterial disease is powerful enough to make genetic
screening of smokers an attractive interventional strategy.
Materials and Methods
Study Participants and Phenotypes
Subjects from a case-control study [21,22] recruited from
Bergen, Norway were used as the discovery cohort in the GWAS.
Baseline characteristics of the subjects are shown in Table 1. The
entry criteria for COPD cases were post-bronchodilator forced
expiratory volume in 1 second (FEV1) ,80% predicted and
FEV1/FVC (forced vital capacity) ,0.7. The controls were
selected based on post-bronchodilator FEV1 .80% predicted
and FEV1/FVC.0.7. Individuals with Pi ZZ, ZNull, Null-Null or
SZ a1-antitrypsin deficiency were excluded. Subjects with chronic
pulmonary disorders other than COPD (e.g., lung cancer,
sarcoidosis, active tuberculosis, and lung fibrosis) were also
excluded. Because of the potential overlap in susceptibility genes
for COPD and asthma, and the difficulty of diagnosing COPD vs.
asthma in smokers with chronic airflow obstruction, previous
asthma diagnosis was not used as an exclusion criterion. Both cases
and controls were required to have a minimum of 2.5 pack-years
of smoking. A total of 823 COPD cases and 810 controls were
included in the present analysis. All of the subjects used in the
primary and replication populations were current or former
smokers (Table 1). Although the mean number of pack-years
smoked was higher in cases (mean 32 SD 18) compared with
controls (mean 19 SD 13), subjects with a range of smoking
intensities were included in the analysis. The distribution of pack-
years of smoking in cases and controls in the Bergen cohort is
shown in Figure S3.
Subjects from the International COPD Genetics Network
(ICGN) were used as the primary replication population. In the
multi-center ICGN study [22,23] subjects with known COPD
were recruited as probands, and siblings and available parents
were ascertained through the probands. Inclusion criteria for
probands were post-bronchodilator FEV1,60% predicted and
FEV1/VC ,90% predicted at a relatively early age (45 to
65 years), a$5 pack-year smoking history, and at least one eligible
sibling with a$5 pack-year smoking history. COPD in siblings was
defined by a post-bronchodilator FEV1,80% predicted and
FEV1/VC,90% predicted. The same exclusion criteria used in
the Bergen study were also applied for the ICGN population. In
total, 1891 Caucasian individuals from 606 pedigrees were
included in the ICGN family-based association analysis.
The second replication cohort included 389 non-Hispanic white
COPD cases from the U.S. National Emphysema Treatment Trial
(NETT) [24] and 472 non-Hispanic white control subjects from
the Normative Aging Study (NAS) [25]. Subjects in NETT had
severe COPD (FEV1 #45% predicted) and bilateral emphysema
on chest CT; all NETT subjects were former smokers. Control
subjects from the NAS had normal spirometry and at least 10
pack-years of cigarette smoking history. Subjects from extended
pedigrees in the Boston Early-Onset COPD (BEOCOPD) study
were used as an additional family-based replication cohort.
BEOCOPD subjects were recruited through COPD probands
with age ,53 years, FEV1 ,40% predicted, and without severe
a1-antitrypsin deficiency [26]. The BEOCOPD analysis included
949 individuals from 127 pedigrees.
Finally, to estimate allele frequencies in the general population
in Norway we used 551 children (all non-smoking) from the
Environment and Childhood Asthma (ECA) birth cohort study in
Oslo [27].
All participants provided written informed consent and local
institutional review boards approved the study protocols.
Genotyping and Quality Control
All samples in the Bergen discovery cohort were genotyped
using Illumina’s HumanHap550 genotyping BeadChip (version 3)
which contains 561,466 single nucleotide polymorphisms (SNPs).
All samples that had a call rate,98%, and all SNPs that had a call
frequency ,99% were deleted. This resulted in the elimination of
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23,436 SNPs from further analysis (See Text S1 for more details).
The ICGN subjects were genotyped using Sequenom’s iPLEX
SNP genotyping protocol developed for measurement with the
MassARRAY mass spectrometer [28]. Genotyping in the NETT/
NAS and BEOCOPD studies was performed using Sequenom
iPLEX or Applied Biosystems TaqMan assays. Genotyping in the
Norwegian ECA Birth cohort was done by TaqMan.
Statistical Analysis
For the association analyses COPD affection status in the Norway
discovery cohort, we used a logistic regression model to perform
single-marker genotype trend tests for the QC-passed SNPs. To
control for the possibility of spurious associations resulting from
population stratification, we used a modified EIGENSTRAT
method [29] (and Text S1). This showed that there were 12
significant principal component axes, all of which were included in
the model. We included age and sex, and since smoking effects are
known to influence COPD risk, we also included current smoking
status and pack-years of smoking as co-variates.
The top 100 SNPs showing the lowest P values in this stage were
selected for assessment in replication cohorts. For replication, we
used a two stage strategy using three independent cohorts
(Figure 1). In the first stage, family-based association analysis for
COPD affection status was conducted in the ICGN data using
PBAT version 3.6 [30]. Adjustments for age, gender, pack-years of
smoking, current smoking status and center were performed in
order to take into account the effect of smoking on the association
results. Association with FEV1 was also tested using PBAT with
age, gender, pack-years of smoking, current smoking status and
height as co-variates. Gene-by-environment interaction analyses
were also conducted using the PBAT program. Biallelic tests were
conducted for SNPs using an additive genetic model. In the second
stage the NETT case-control study was analyzed for the presence/
absence of COPD using an additive genetic model. An unadjusted
analysis and a logistic regression model adjusted for age and pack-
years of smoking were conducted; sex was not included as a
covariate because all NAS subjects were male, and current
smoking was not included because all NETT subjects were ex-
smokers. The BEOCOPD family-based study in the validation
stage was analyzed using PBAT version 3.6 [30]. COPD was
defined by post-bronchodilator FEV1/FVC,0.7 and FEV1,80%
predicted (GOLD stage 2 or greater). Because a broad range of
FEV1 values were included in the BEOCOPD study, we also
analyzed FEV1 as a quantitative outcome in that population.
Analysis of post-bronchodilator values of FEV1 was adjusted for
ever-smoking status, pack-years of smoking, age, sex, and height.
Adjustments for Multiple Comparisons
We assessed genome-wide significance with a Bonferroni
correction (p cutoff = 1.01361027 considering 493,609 indepen-
dent tests in the Bergen cohort (see Text S1), 100 tests in the
ICGN cohort, 7 tests in the NETT/NAS study and 6 tests in the
BEOCOPD study (Total 493,772 tests).
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